Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Tonix Pharmaceuticals Holding Corp(TNXP)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for TNXP
09/25/2026: TNXP (1-star) is currently NOT-A-BUY. Pass it for now.
Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapies for CNS disorders and immunology, including promising candidates for fibromyalgia and transplant rejection. Its main strength lies in its diverse pipeline and proprietary drug delivery technologies. The primary investment story rests on the potential for clinical trial success and subsequent regulatory approval of these key candidates. However, the company faces significant risks, including consistent financial losses, reliance on dilutive financing, and intense competition from large pharmaceutical firms. The stock best suits high-risk growth investors who can monitor clinical milestones closely, rather than those seeking established earnings or dividend income.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward speculative exposure to clinical breakthroughs. |
| Momentum investor | Strong fit while signal remains positive | Stock volatility often draws momentum traders during clinical data release periods. |
| Value investor | Weak fit | The lack of earnings and reliance on dilution makes this a poor fit for traditional value strategies. |
| Dividend investor | Weak fit | Tonix does not pay dividends and prioritizes cash preservation for R&D. |
| Low-risk investor | Weak fit | The high volatility and clinical failure risk are unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks are highly sensitive to news and trial results. |
| Valuation risk | High | Without revenue, valuation is subjective and prone to sudden shifts. |
| Competition risk (Pharmaceutical giants) | High | Large competitors can outspend and out-market smaller entities. |
| Business quality | Medium | The company is early-stage, meaning the business model is not yet proven. |
| Dividend income | Low / none | Investors should not expect income from this stock. |
| Execution risk | High | Failure to achieve regulatory approval would significantly damage shareholder value. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -50.05% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 169.11M USD | Price to earnings Ratio - | 1Y Target Price 44.5 |
Price to earnings Ratio - | 1Y Target Price 44.5 | ||
Volume (30-day avg) 458.5K shares | Beta 1.75 | 52 Weeks Range 9.40 - 25.52 | Updated Date 09/27/2026 |
52 Weeks Range 9.40 - 25.52 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -13.09 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Research and development of potential therapies for fibromyalgia and organ transplant rejection. | The company is currently burning cash to develop drugs; it does not yet make money from product sales. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1.01M | Price to Sales(TTM) 5.81 |
Enterprise Value 1.01M | Price to Sales(TTM) 5.81 | ||
Enterprise Value to Revenue 0.03 | Enterprise Value to EBITDA 0.94 | Shares Outstanding 17.15M | Shares Floating 14.12M |
Shares Outstanding 17.15M | Shares Floating 14.12M | ||
Percent Insiders 0.16 | Percent Institutions 56.05 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Tonix Pharmaceuticals Holding Corp
Exchange NASDAQ | Headquarters Berkeley Heights, NJ, United States | ||
IPO Launch date 2012-05-10 | Co-Founder, Interim Chief Medical Officer, President, CEO & Chairman Dr. Seth Lederman M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 142 | Website https://www.tonixpharma.com |
Full time employees 142 | Website https://www.tonixpharma.com | ||
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome. Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.